Literature DB >> 12380668

Use of antihistamine drugs in early pregnancy and delivery outcome.

B Källén1.   

Abstract

OBJECTIVE: To study the impact of antihistamine use in early pregnancy on delivery outcome.
METHODS: Using prospectively collected information on drug use in early pregnancy, delivery outcome was studied among 17 266 women with 17 776 deliveries and 18 197 infants. The analysis was performed according to the main reason for antihistamine use: nausea and vomiting in pregnancy and allergy.
RESULTS: In the nausea and vomiting in pregnancy group, we found a significant increase in twin births and a significant reduction in preterm births, low birth weight and being small-for-gestational age among singletons. The perinatal death rate was reduced and the rate of congenital malformations was normal. A reduction was seen in the occurrence of congenital cardiovascular defects after the use of antihistamines. The odds ratio for specified cardiac defects, with the exception of ventricular and atrium septal defects, after the use of antihistamines for nausea and vomiting in pregnancy (0.54) was significantly lower than that for non-cardiovascular congenital malformations (0.95). No statistically significant effects on delivery outcome were seen after the use of antihistamine drugs for allergy. However, there was a non-significant tendency for a reduced risk for cardiovascular defects (odds ratio 0.71).
CONCLUSIONS: The beneficial effects on delivery outcome observed are most probably related to the underlying nausea and vomiting in pregnancy. There is no clear teratogenic effect of the antihistamines studied.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12380668     DOI: 10.1080/jmf.11.3.146.152

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  25 in total

1.  Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data.

Authors:  Deborah Layton; Vicki Osborne; Anna Gilchrist; Saad A W Shakir
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

2.  Birth defects and disabilities: a public health issue for the 21st century.

Authors:  Coleen A Boyle; José F Cordero
Journal:  Am J Public Health       Date:  2005-09-29       Impact factor: 9.308

3.  Use of antiemetic drugs during pregnancy in Sweden.

Authors:  Charlotte Asker; B Norstedt Wikner; Bengt Källén
Journal:  Eur J Clin Pharmacol       Date:  2005-11-18       Impact factor: 2.953

4.  The safety or risk of antihistamine use in pregnancy: reassuring data are helpful but not sufficient.

Authors:  Margaret A Honein; Cynthia A Moore
Journal:  J Allergy Clin Immunol Pract       Date:  2013-10-31

5.  Assessment of antihistamine use in early pregnancy and birth defects.

Authors:  Qian Li; Allen A Mitchell; Martha M Werler; Wai-Ping Yau; Sonia Hernández-Díaz
Journal:  J Allergy Clin Immunol Pract       Date:  2013-09-12

Review 6.  The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis.

Authors:  Fatma Etwel; Lauren H Faught; Michael J Rieder; Gideon Koren
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

Review 7.  Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review.

Authors:  Cameron Gilbert; Paolo Mazzotta; Ronen Loebstein; Gideon Koren
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 8.  Asthma Outcomes and Management During Pregnancy.

Authors:  Catherine A Bonham; Karen C Patterson; Mary E Strek
Journal:  Chest       Date:  2017-09-01       Impact factor: 9.410

9.  Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England.

Authors:  Deborah Layton; Lynda Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 10.  Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysis.

Authors:  Eleanor B Schwarz; Myla E Moretti; Smita Nayak; Gideon Koren
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.